 Douglas Fish
Concepts (583)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Infective Agents | 19 | 2016 | 225 | 2.350 |
Why?
| | Anti-Bacterial Agents | 28 | 2022 | 1477 | 1.970 |
Why?
| | Vancomycin | 6 | 2024 | 75 | 1.400 |
Why?
| | Staphylococcal Infections | 5 | 2022 | 336 | 1.340 |
Why?
| | Surgical Wound Infection | 6 | 2016 | 248 | 1.150 |
Why?
| | Sepsis | 7 | 2020 | 508 | 1.080 |
Why?
| | Microbial Sensitivity Tests | 15 | 2022 | 301 | 1.040 |
Why?
| | Critical Illness | 22 | 2022 | 643 | 1.010 |
Why?
| | Endocarditis | 3 | 2024 | 32 | 1.010 |
Why?
| | Antibiotic Prophylaxis | 7 | 2016 | 96 | 0.920 |
Why?
| | Endocarditis, Bacterial | 1 | 2024 | 36 | 0.890 |
Why?
| | Levofloxacin | 6 | 2006 | 22 | 0.870 |
Why?
| | Ofloxacin | 6 | 2006 | 22 | 0.870 |
Why?
| | Pseudomonas Infections | 5 | 2013 | 185 | 0.860 |
Why?
| | Prodrugs | 4 | 2009 | 42 | 0.830 |
Why?
| | Cephalexin | 1 | 2022 | 8 | 0.820 |
Why?
| | Fluoroquinolones | 7 | 2007 | 41 | 0.820 |
Why?
| | Bacterial Infections | 7 | 2009 | 219 | 0.780 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 243 | 0.750 |
Why?
| | Hemofiltration | 8 | 2022 | 31 | 0.740 |
Why?
| | Cross Infection | 6 | 2011 | 197 | 0.730 |
Why?
| | Intensive Care Units | 16 | 2016 | 619 | 0.730 |
Why?
| | Renal Replacement Therapy | 4 | 2015 | 66 | 0.700 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2020 | 191 | 0.700 |
Why?
| | Anticoagulants | 6 | 2016 | 547 | 0.700 |
Why?
| | Heparin | 6 | 2016 | 222 | 0.680 |
Why?
| | Antiviral Agents | 6 | 2012 | 647 | 0.670 |
Why?
| | Acute Kidney Injury | 4 | 2024 | 638 | 0.660 |
Why?
| | Education, Pharmacy | 2 | 2014 | 128 | 0.660 |
Why?
| | Critical Care | 11 | 2016 | 474 | 0.620 |
Why?
| | Valine | 5 | 2008 | 72 | 0.590 |
Why?
| | Vitreous Body | 2 | 2009 | 101 | 0.590 |
Why?
| | beta-Lactams | 2 | 2020 | 27 | 0.590 |
Why?
| | Acyclovir | 5 | 2008 | 100 | 0.590 |
Why?
| | Humans | 122 | 2024 | 114937 | 0.560 |
Why?
| | Cefoxitin | 1 | 2016 | 8 | 0.550 |
Why?
| | Pseudomonas aeruginosa | 6 | 2013 | 299 | 0.530 |
Why?
| | Obesity, Morbid | 2 | 2016 | 197 | 0.530 |
Why?
| | Middle Aged | 52 | 2024 | 26806 | 0.520 |
Why?
| | Antifungal Agents | 6 | 2019 | 129 | 0.490 |
Why?
| | Students, Pharmacy | 2 | 2014 | 100 | 0.490 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 25 | 0.480 |
Why?
| | Pharmacy Service, Hospital | 3 | 2014 | 84 | 0.480 |
Why?
| | Histamine H2 Antagonists | 1 | 2014 | 29 | 0.470 |
Why?
| | Thrombocytopenia | 3 | 2009 | 177 | 0.470 |
Why?
| | Drug Resistance, Microbial | 4 | 2006 | 67 | 0.470 |
Why?
| | Pneumonia | 4 | 2014 | 568 | 0.470 |
Why?
| | Problem-Based Learning | 2 | 2017 | 78 | 0.470 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 96 | 0.450 |
Why?
| | Peritonitis | 2 | 2016 | 76 | 0.440 |
Why?
| | Aged | 36 | 2024 | 19122 | 0.430 |
Why?
| | Pneumonia, Bacterial | 2 | 2013 | 106 | 0.430 |
Why?
| | Hirudins | 4 | 2010 | 46 | 0.430 |
Why?
| | Hepatorenal Syndrome | 3 | 2013 | 14 | 0.430 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 141 | 0.430 |
Why?
| | Adult | 46 | 2024 | 30608 | 0.430 |
Why?
| | Voriconazole | 3 | 2019 | 24 | 0.430 |
Why?
| | Colorectal Surgery | 1 | 2012 | 21 | 0.420 |
Why?
| | Liver Cirrhosis | 3 | 2009 | 228 | 0.410 |
Why?
| | Administration, Oral | 11 | 2019 | 731 | 0.410 |
Why?
| | Male | 61 | 2024 | 55663 | 0.400 |
Why?
| | Teaching | 1 | 2014 | 223 | 0.390 |
Why?
| | Burns | 3 | 2018 | 237 | 0.380 |
Why?
| | Preoperative Care | 2 | 2012 | 317 | 0.380 |
Why?
| | Cephalosporins | 3 | 2012 | 26 | 0.380 |
Why?
| | Enteral Nutrition | 4 | 2008 | 157 | 0.370 |
Why?
| | Interpersonal Relations | 1 | 2014 | 339 | 0.370 |
Why?
| | Female | 58 | 2024 | 59581 | 0.360 |
Why?
| | Cefazolin | 2 | 2022 | 18 | 0.360 |
Why?
| | Staphylococcus aureus | 3 | 2022 | 385 | 0.360 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 19 | 0.360 |
Why?
| | Imipenem | 3 | 2010 | 16 | 0.360 |
Why?
| | Chromatography, High Pressure Liquid | 9 | 2012 | 474 | 0.350 |
Why?
| | Syringes | 2 | 2007 | 41 | 0.350 |
Why?
| | Penicillanic Acid | 2 | 2013 | 4 | 0.340 |
Why?
| | Dexmedetomidine | 3 | 2014 | 45 | 0.340 |
Why?
| | Retrospective Studies | 23 | 2024 | 12544 | 0.330 |
Why?
| | 2-Aminopurine | 1 | 2009 | 10 | 0.330 |
Why?
| | Peptide Fragments | 3 | 2010 | 668 | 0.330 |
Why?
| | HIV Protease Inhibitors | 2 | 2000 | 64 | 0.330 |
Why?
| | Recombinant Proteins | 6 | 2010 | 1233 | 0.320 |
Why?
| | Peptic Ulcer | 2 | 2014 | 14 | 0.310 |
Why?
| | Monte Carlo Method | 3 | 2016 | 137 | 0.300 |
Why?
| | Drug Delivery Systems | 2 | 2006 | 296 | 0.300 |
Why?
| | Aged, 80 and over | 15 | 2018 | 6364 | 0.290 |
Why?
| | Infection Control | 3 | 2010 | 135 | 0.290 |
Why?
| | Protein C | 2 | 2010 | 45 | 0.290 |
Why?
| | Drug Monitoring | 6 | 2017 | 184 | 0.290 |
Why?
| | Polypropylenes | 1 | 2007 | 14 | 0.290 |
Why?
| | Hypnotics and Sedatives | 3 | 2014 | 134 | 0.290 |
Why?
| | Sympathomimetics | 1 | 2007 | 25 | 0.290 |
Why?
| | Phenylephrine | 1 | 2007 | 74 | 0.290 |
Why?
| | Expectorants | 1 | 2007 | 24 | 0.280 |
Why?
| | Triazoles | 2 | 2019 | 130 | 0.280 |
Why?
| | Accreditation | 1 | 2007 | 78 | 0.280 |
Why?
| | Clarithromycin | 2 | 1999 | 25 | 0.280 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 45 | 0.280 |
Why?
| | Educational Measurement | 3 | 2017 | 257 | 0.280 |
Why?
| | Drug Packaging | 1 | 2007 | 43 | 0.270 |
Why?
| | Acetylcysteine | 1 | 2007 | 142 | 0.260 |
Why?
| | Models, Biological | 1 | 2013 | 1630 | 0.260 |
Why?
| | Kidney Diseases | 3 | 2009 | 350 | 0.260 |
Why?
| | Piperacillin | 2 | 2013 | 8 | 0.260 |
Why?
| | Pipecolic Acids | 1 | 2005 | 23 | 0.260 |
Why?
| | Prospective Studies | 15 | 2018 | 6218 | 0.260 |
Why?
| | Penicillins | 2 | 2004 | 52 | 0.260 |
Why?
| | Drug Interactions | 6 | 2013 | 347 | 0.260 |
Why?
| | Ketolides | 1 | 2005 | 1 | 0.250 |
Why?
| | Nursing Homes | 3 | 2011 | 136 | 0.250 |
Why?
| | Bacteria | 4 | 2022 | 728 | 0.250 |
Why?
| | Thrombin | 1 | 2006 | 140 | 0.250 |
Why?
| | HIV Infections | 6 | 2013 | 2470 | 0.240 |
Why?
| | Bacteremia | 3 | 2018 | 159 | 0.240 |
Why?
| | Enterobacter cloacae | 1 | 2004 | 3 | 0.230 |
Why?
| | Aza Compounds | 1 | 2004 | 11 | 0.230 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2542 | 0.230 |
Why?
| | Acinetobacter baumannii | 1 | 2004 | 15 | 0.230 |
Why?
| | Obesity | 1 | 2016 | 2514 | 0.230 |
Why?
| | Respiratory Tract Infections | 2 | 2005 | 321 | 0.230 |
Why?
| | Klebsiella pneumoniae | 1 | 2004 | 41 | 0.230 |
Why?
| | Anticonvulsants | 2 | 2017 | 178 | 0.220 |
Why?
| | Area Under Curve | 6 | 2008 | 275 | 0.220 |
Why?
| | Liver Diseases | 1 | 2006 | 254 | 0.220 |
Why?
| | Drug Storage | 4 | 2007 | 59 | 0.220 |
Why?
| | Half-Life | 5 | 2012 | 141 | 0.220 |
Why?
| | Drug Stability | 4 | 2007 | 151 | 0.210 |
Why?
| | Tissue Distribution | 3 | 2016 | 285 | 0.210 |
Why?
| | Quinolines | 1 | 2004 | 129 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2016 | 1856 | 0.210 |
Why?
| | Anti-HIV Agents | 2 | 1999 | 668 | 0.210 |
Why?
| | Cefadroxil | 1 | 2022 | 6 | 0.210 |
Why?
| | Cephalothin | 1 | 2022 | 6 | 0.210 |
Why?
| | Oxacillin | 1 | 2022 | 6 | 0.210 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 1993 | 117 | 0.210 |
Why?
| | Liver Transplantation | 1 | 2009 | 706 | 0.210 |
Why?
| | Methicillin | 1 | 2022 | 11 | 0.210 |
Why?
| | Drug Therapy, Combination | 8 | 2016 | 954 | 0.200 |
Why?
| | Infusions, Intravenous | 7 | 2016 | 372 | 0.200 |
Why?
| | Quinolones | 1 | 2003 | 97 | 0.200 |
Why?
| | Bronchi | 1 | 2003 | 243 | 0.200 |
Why?
| | Kidney Failure, Chronic | 5 | 2016 | 488 | 0.200 |
Why?
| | Lorazepam | 2 | 2014 | 23 | 0.200 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2014 | 159 | 0.200 |
Why?
| | Antacids | 1 | 2001 | 15 | 0.200 |
Why?
| | Bronchoscopy | 1 | 2003 | 246 | 0.200 |
Why?
| | Catheters, Indwelling | 2 | 2016 | 79 | 0.190 |
Why?
| | Colorado | 12 | 2021 | 4091 | 0.190 |
Why?
| | Hemodiafiltration | 2 | 2005 | 9 | 0.190 |
Why?
| | Fibrinolytic Agents | 2 | 2016 | 233 | 0.190 |
Why?
| | Ciprofloxacin | 3 | 2004 | 23 | 0.190 |
Why?
| | Lung Transplantation | 2 | 2014 | 246 | 0.180 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 752 | 0.180 |
Why?
| | Clinical Competence | 1 | 2007 | 901 | 0.180 |
Why?
| | Antidiarrheals | 1 | 2000 | 15 | 0.180 |
Why?
| | Fludrocortisone | 1 | 2000 | 3 | 0.180 |
Why?
| | Mineralocorticoids | 1 | 2000 | 3 | 0.180 |
Why?
| | Naphthyridines | 1 | 2000 | 16 | 0.180 |
Why?
| | Public Health Administration | 1 | 2021 | 75 | 0.180 |
Why?
| | Octreotide | 2 | 2013 | 25 | 0.170 |
Why?
| | Multivariate Analysis | 6 | 2017 | 1440 | 0.170 |
Why?
| | Ethanol | 2 | 2014 | 548 | 0.170 |
Why?
| | Hyperkalemia | 1 | 2000 | 26 | 0.170 |
Why?
| | Multiple Organ Failure | 2 | 2010 | 142 | 0.170 |
Why?
| | Practice Guidelines as Topic | 5 | 2016 | 1400 | 0.170 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 240 | 0.170 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| | Diarrhea | 1 | 2000 | 173 | 0.160 |
Why?
| | Thienamycins | 2 | 2005 | 4 | 0.160 |
Why?
| | Cytosine | 1 | 1999 | 45 | 0.160 |
Why?
| | Cohort Studies | 7 | 2013 | 4903 | 0.160 |
Why?
| | Hydroxyurea | 1 | 1999 | 30 | 0.160 |
Why?
| | Nafcillin | 1 | 2018 | 3 | 0.160 |
Why?
| | Clostridium Infections | 1 | 2019 | 56 | 0.160 |
Why?
| | APACHE | 3 | 2010 | 58 | 0.160 |
Why?
| | Organophosphonates | 1 | 1999 | 91 | 0.160 |
Why?
| | Organophosphorus Compounds | 1 | 1999 | 72 | 0.160 |
Why?
| | Schools, Pharmacy | 2 | 2017 | 52 | 0.160 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1998 | 82 | 0.150 |
Why?
| | Nitriles | 1 | 2019 | 151 | 0.150 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 152 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2020 | 130 | 0.150 |
Why?
| | Vitrectomy | 2 | 2009 | 57 | 0.150 |
Why?
| | Treatment Outcome | 10 | 2018 | 9105 | 0.150 |
Why?
| | Gastric Emptying | 2 | 2008 | 40 | 0.150 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 1997 | 8 | 0.150 |
Why?
| | Vecuronium Bromide | 1 | 1997 | 6 | 0.150 |
Why?
| | Pharmaceutical Services | 1 | 1998 | 79 | 0.150 |
Why?
| | Atracurium | 1 | 1997 | 13 | 0.150 |
Why?
| | Lyme Disease | 3 | 2000 | 32 | 0.150 |
Why?
| | Cardiopulmonary Bypass | 2 | 2016 | 176 | 0.150 |
Why?
| | Bites and Stings | 3 | 2000 | 30 | 0.150 |
Why?
| | Sumatriptan | 1 | 1997 | 6 | 0.150 |
Why?
| | Hematologic Neoplasms | 1 | 2019 | 136 | 0.150 |
Why?
| | Gastrointestinal Agents | 2 | 2008 | 60 | 0.150 |
Why?
| | Serotonin Receptor Agonists | 1 | 1997 | 27 | 0.150 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 119 | 0.140 |
Why?
| | Piracetam | 1 | 2017 | 14 | 0.140 |
Why?
| | Immunity, Humoral | 1 | 2018 | 112 | 0.140 |
Why?
| | Vasodilator Agents | 2 | 2016 | 305 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 21 | 0.140 |
Why?
| | Hydrogen-Ion Concentration | 4 | 2014 | 512 | 0.140 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 132 | 0.140 |
Why?
| | Drug Administration Schedule | 5 | 2018 | 718 | 0.140 |
Why?
| | Neurosurgical Procedures | 1 | 2018 | 154 | 0.140 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 76 | 0.140 |
Why?
| | Pneumonectomy | 1 | 1998 | 125 | 0.140 |
Why?
| | Administration, Intravenous | 2 | 2017 | 125 | 0.140 |
Why?
| | Thiocyanates | 1 | 2016 | 29 | 0.130 |
Why?
| | Nitroprusside | 1 | 2016 | 64 | 0.130 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.130 |
Why?
| | Benzodiazepines | 2 | 2014 | 116 | 0.130 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2005 | 63 | 0.130 |
Why?
| | Toxoplasmosis, Cerebral | 1 | 1995 | 2 | 0.130 |
Why?
| | Partial Thromboplastin Time | 2 | 2006 | 51 | 0.130 |
Why?
| | Naphthoquinones | 1 | 1995 | 17 | 0.130 |
Why?
| | Famotidine | 1 | 1995 | 2 | 0.130 |
Why?
| | Antiprotozoal Agents | 1 | 1995 | 12 | 0.130 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1995 | 26 | 0.130 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 1997 | 61 | 0.130 |
Why?
| | Pyridines | 1 | 2019 | 425 | 0.130 |
Why?
| | Drug Resistance | 2 | 2011 | 158 | 0.120 |
Why?
| | Academic Medical Centers | 2 | 2019 | 415 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 12 | 0.120 |
Why?
| | Peritoneal Dialysis | 1 | 2016 | 83 | 0.120 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.120 |
Why?
| | Body Weight | 2 | 2016 | 868 | 0.120 |
Why?
| | Drug Utilization Review | 1 | 1995 | 57 | 0.120 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 28 | 0.120 |
Why?
| | Anti-Ulcer Agents | 1 | 2014 | 16 | 0.120 |
Why?
| | Antidotes | 1 | 2016 | 135 | 0.120 |
Why?
| | Temperature | 2 | 2007 | 576 | 0.120 |
Why?
| | Diltiazem | 1 | 2014 | 23 | 0.120 |
Why?
| | Biopsy | 1 | 1998 | 1045 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2018 | 776 | 0.110 |
Why?
| | Vasopressins | 2 | 2004 | 56 | 0.110 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2014 | 14 | 0.110 |
Why?
| | Drug Dosage Calculations | 1 | 2014 | 21 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 525 | 0.110 |
Why?
| | Osmotic Pressure | 1 | 2014 | 28 | 0.110 |
Why?
| | Mass Casualty Incidents | 1 | 2014 | 38 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2001 | 945 | 0.110 |
Why?
| | Biological Availability | 4 | 2009 | 119 | 0.110 |
Why?
| | Somatostatin | 1 | 2013 | 52 | 0.110 |
Why?
| | Vasoconstrictor Agents | 2 | 2004 | 112 | 0.110 |
Why?
| | Risk Factors | 9 | 2014 | 8637 | 0.110 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2014 | 102 | 0.110 |
Why?
| | Midazolam | 1 | 2013 | 43 | 0.110 |
Why?
| | Homicide | 1 | 2014 | 53 | 0.110 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 1993 | 21 | 0.110 |
Why?
| | Lung | 2 | 1998 | 3593 | 0.110 |
Why?
| | Injections, Intravenous | 4 | 2012 | 201 | 0.110 |
Why?
| | Zidovudine | 1 | 1993 | 77 | 0.110 |
Why?
| | Nursing Staff | 2 | 2010 | 38 | 0.110 |
Why?
| | Ticks | 2 | 1993 | 12 | 0.110 |
Why?
| | Bacteroides fragilis | 1 | 2012 | 11 | 0.110 |
Why?
| | Conscious Sedation | 1 | 2013 | 79 | 0.110 |
Why?
| | Sirolimus | 1 | 2014 | 181 | 0.110 |
Why?
| | Telemedicine | 1 | 2021 | 665 | 0.110 |
Why?
| | Renal Dialysis | 3 | 2022 | 369 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 824 | 0.100 |
Why?
| | Vasoconstriction | 1 | 2014 | 186 | 0.100 |
Why?
| | Bone Cements | 1 | 1992 | 35 | 0.100 |
Why?
| | Transplant Recipients | 1 | 2014 | 140 | 0.100 |
Why?
| | Coronary Artery Bypass | 1 | 2014 | 198 | 0.100 |
Why?
| | Comprehension | 1 | 2014 | 154 | 0.100 |
Why?
| | Creatinine | 2 | 2007 | 424 | 0.100 |
Why?
| | Shock, Septic | 2 | 2004 | 185 | 0.100 |
Why?
| | Clinical Trials as Topic | 4 | 2000 | 934 | 0.100 |
Why?
| | Mental Recall | 1 | 2013 | 170 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1993 | 218 | 0.100 |
Why?
| | Treatment Failure | 1 | 2013 | 332 | 0.100 |
Why?
| | Long QT Syndrome | 1 | 2013 | 59 | 0.100 |
Why?
| | Enterococcus | 1 | 1992 | 18 | 0.100 |
Why?
| | Educational Status | 1 | 2014 | 409 | 0.100 |
Why?
| | Ganciclovir | 1 | 2012 | 49 | 0.100 |
Why?
| | Occupational Diseases | 1 | 1993 | 128 | 0.100 |
Why?
| | Curriculum | 2 | 2017 | 845 | 0.100 |
Why?
| | Metoclopramide | 2 | 2008 | 16 | 0.100 |
Why?
| | Erythromycin | 2 | 2008 | 24 | 0.100 |
Why?
| | Drug Resistance, Multiple, Fungal | 1 | 2011 | 1 | 0.100 |
Why?
| | Metabolic Clearance Rate | 4 | 2012 | 104 | 0.100 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 175 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 3 | 2014 | 1177 | 0.090 |
Why?
| | Candida | 1 | 2011 | 32 | 0.090 |
Why?
| | Traction | 1 | 1991 | 15 | 0.090 |
Why?
| | Adolescent | 12 | 2018 | 17829 | 0.090 |
Why?
| | Primary Health Care | 1 | 2021 | 1515 | 0.090 |
Why?
| | Candidiasis | 1 | 2011 | 52 | 0.090 |
Why?
| | Wounds, Gunshot | 1 | 2014 | 188 | 0.090 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 24 | 0.090 |
Why?
| | Anti-Anxiety Agents | 1 | 1991 | 43 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 612 | 0.090 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 22 | 0.090 |
Why?
| | Suspensions | 3 | 2002 | 30 | 0.090 |
Why?
| | Hip Dislocation, Congenital | 1 | 1991 | 38 | 0.090 |
Why?
| | Genes, Regulator | 1 | 2010 | 34 | 0.090 |
Why?
| | Vancomycin Resistance | 1 | 2010 | 15 | 0.090 |
Why?
| | Recurrence | 2 | 2009 | 937 | 0.090 |
Why?
| | Delirium | 1 | 1991 | 66 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2002 | 82 | 0.090 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 67 | 0.090 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 11 | 0.090 |
Why?
| | Propylene Glycol | 1 | 2009 | 9 | 0.090 |
Why?
| | Electrocardiography | 1 | 2013 | 562 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2011 | 490 | 0.090 |
Why?
| | Aortic Valve | 1 | 2014 | 401 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 319 | 0.090 |
Why?
| | Cytomegalovirus Infections | 1 | 2012 | 183 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1700 | 0.080 |
Why?
| | Young Adult | 5 | 2019 | 10478 | 0.080 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2009 | 9 | 0.080 |
Why?
| | Eye Infections, Viral | 1 | 2009 | 7 | 0.080 |
Why?
| | Double-Blind Method | 5 | 2014 | 1663 | 0.080 |
Why?
| | Antipsychotic Agents | 1 | 1991 | 184 | 0.080 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 38 | 0.080 |
Why?
| | Regression Analysis | 4 | 2016 | 947 | 0.080 |
Why?
| | Education, Continuing | 1 | 2009 | 39 | 0.080 |
Why?
| | Escherichia coli | 1 | 2012 | 722 | 0.080 |
Why?
| | Tick Infestations | 1 | 1988 | 4 | 0.080 |
Why?
| | Models, Statistical | 1 | 2012 | 604 | 0.080 |
Why?
| | Patients | 1 | 2010 | 162 | 0.080 |
Why?
| | Communication | 1 | 2014 | 749 | 0.080 |
Why?
| | Time Factors | 7 | 2014 | 6125 | 0.080 |
Why?
| | Acetaminophen | 2 | 2008 | 238 | 0.080 |
Why?
| | Immunization Programs | 1 | 2010 | 206 | 0.080 |
Why?
| | Health Personnel | 1 | 1993 | 574 | 0.070 |
Why?
| | Pharmacists | 3 | 2020 | 236 | 0.070 |
Why?
| | Antitubercular Agents | 2 | 1999 | 169 | 0.070 |
Why?
| | Lung Diseases | 1 | 2014 | 703 | 0.070 |
Why?
| | Incidence | 3 | 2006 | 2316 | 0.070 |
Why?
| | Cost Control | 1 | 2007 | 38 | 0.070 |
Why?
| | Chronic Disease | 1 | 2013 | 1593 | 0.070 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2007 | 28 | 0.070 |
Why?
| | Child | 4 | 2022 | 18366 | 0.070 |
Why?
| | Glutamine | 1 | 2007 | 91 | 0.070 |
Why?
| | Cerebrospinal Fluid | 1 | 2007 | 90 | 0.070 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 117 | 0.070 |
Why?
| | United States | 6 | 2014 | 12211 | 0.070 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 19 | 0.070 |
Why?
| | Drug Costs | 2 | 1999 | 91 | 0.060 |
Why?
| | Preceptorship | 1 | 2006 | 63 | 0.060 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 71 | 0.060 |
Why?
| | Cilastatin | 1 | 2005 | 2 | 0.060 |
Why?
| | Platelet Activation | 1 | 2005 | 68 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 46 | 0.060 |
Why?
| | Chromatography, Liquid | 1 | 2007 | 348 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2005 | 94 | 0.060 |
Why?
| | Cyclosporine | 2 | 2006 | 161 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2014 | 3008 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2324 | 0.060 |
Why?
| | Central Nervous System | 1 | 2007 | 238 | 0.060 |
Why?
| | Protease Inhibitors | 1 | 2005 | 99 | 0.060 |
Why?
| | Influenza, Human | 1 | 2010 | 546 | 0.060 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 53 | 0.060 |
Why?
| | Arginine | 1 | 2005 | 237 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2016 | 387 | 0.060 |
Why?
| | Acinetobacter Infections | 1 | 2004 | 10 | 0.060 |
Why?
| | Immunosuppressive Agents | 2 | 2014 | 648 | 0.060 |
Why?
| | Animals | 9 | 2014 | 31839 | 0.060 |
Why?
| | Klebsiella Infections | 1 | 2004 | 23 | 0.060 |
Why?
| | Surveys and Questionnaires | 5 | 2014 | 4635 | 0.060 |
Why?
| | Colony Count, Microbial | 1 | 2004 | 111 | 0.060 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2006 | 176 | 0.060 |
Why?
| | Enterobacteriaceae Infections | 1 | 2004 | 32 | 0.060 |
Why?
| | Graft vs Host Disease | 1 | 2006 | 215 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2009 | 542 | 0.060 |
Why?
| | DNA | 1 | 2010 | 1351 | 0.060 |
Why?
| | Staphylococcal Skin Infections | 1 | 2003 | 29 | 0.050 |
Why?
| | Cross-Sectional Studies | 4 | 2014 | 4407 | 0.050 |
Why?
| | Drug Synergism | 1 | 2004 | 316 | 0.050 |
Why?
| | Gestational Age | 1 | 2006 | 759 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2002 | 59 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 1 | 2006 | 345 | 0.050 |
Why?
| | Kidney Function Tests | 1 | 2003 | 140 | 0.050 |
Why?
| | Transcription Factors | 1 | 2010 | 1530 | 0.050 |
Why?
| | Respiration, Artificial | 2 | 2014 | 526 | 0.050 |
Why?
| | Infant, Premature | 1 | 2006 | 478 | 0.050 |
Why?
| | Sulfonamides | 1 | 2005 | 445 | 0.050 |
Why?
| | Clinical Protocols | 2 | 1995 | 232 | 0.050 |
Why?
| | Computer Simulation | 1 | 2006 | 880 | 0.050 |
Why?
| | Hospitalization | 1 | 2010 | 1754 | 0.050 |
Why?
| | Osmolar Concentration | 2 | 2002 | 174 | 0.050 |
Why?
| | Kansas | 2 | 2011 | 29 | 0.050 |
Why?
| | Iridium Radioisotopes | 1 | 2001 | 5 | 0.050 |
Why?
| | Missouri | 2 | 2011 | 62 | 0.050 |
Why?
| | Pharmacokinetics | 1 | 2001 | 25 | 0.050 |
Why?
| | Azithromycin | 1 | 2001 | 80 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2004 | 1215 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2007 | 5035 | 0.050 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2002 | 72 | 0.050 |
Why?
| | Arachnid Vectors | 1 | 2000 | 3 | 0.050 |
Why?
| | Borrelia burgdorferi Group | 1 | 2000 | 8 | 0.050 |
Why?
| | Surgical Procedures, Operative | 2 | 2013 | 206 | 0.040 |
Why?
| | Ixodes | 1 | 2000 | 10 | 0.040 |
Why?
| | Milk, Human | 1 | 2002 | 128 | 0.040 |
Why?
| | Aldosterone | 1 | 2000 | 42 | 0.040 |
Why?
| | Brachytherapy | 1 | 2001 | 104 | 0.040 |
Why?
| | Health Plan Implementation | 1 | 2021 | 132 | 0.040 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2000 | 38 | 0.040 |
Why?
| | Ethionamide | 1 | 1999 | 1 | 0.040 |
Why?
| | Aminosalicylic Acid | 1 | 1999 | 1 | 0.040 |
Why?
| | Cycloserine | 1 | 1999 | 3 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2000 | 86 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 3354 | 0.040 |
Why?
| | Renal Insufficiency | 1 | 2001 | 136 | 0.040 |
Why?
| | Potassium | 1 | 2000 | 128 | 0.040 |
Why?
| | Clofazimine | 1 | 1999 | 14 | 0.040 |
Why?
| | Pyrazinamide | 1 | 1999 | 6 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2000 | 141 | 0.040 |
Why?
| | Hydroxylation | 1 | 1999 | 29 | 0.040 |
Why?
| | Age Factors | 3 | 2013 | 2891 | 0.040 |
Why?
| | Ethambutol | 1 | 1999 | 20 | 0.040 |
Why?
| | Antibiotics, Antitubercular | 1 | 1999 | 35 | 0.040 |
Why?
| | Drug Combinations | 1 | 2000 | 286 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 281 | 0.040 |
Why?
| | Virus Activation | 1 | 1999 | 78 | 0.040 |
Why?
| | Length of Stay | 3 | 2014 | 949 | 0.040 |
Why?
| | Molecular Structure | 1 | 2000 | 438 | 0.040 |
Why?
| | Cornea | 1 | 1999 | 107 | 0.040 |
Why?
| | Isoniazid | 1 | 1999 | 52 | 0.040 |
Why?
| | Eye | 1 | 1999 | 101 | 0.040 |
Why?
| | Herpesvirus 1, Human | 1 | 1999 | 76 | 0.040 |
Why?
| | Rifampin | 1 | 1999 | 68 | 0.040 |
Why?
| | Vascular Grafting | 1 | 2018 | 12 | 0.040 |
Why?
| | Coronary Disease | 1 | 2001 | 347 | 0.040 |
Why?
| | Venous Thrombosis | 1 | 2000 | 142 | 0.040 |
Why?
| | Laser Therapy | 1 | 1999 | 100 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1999 | 257 | 0.040 |
Why?
| | Drug Resistance, Viral | 1 | 1999 | 99 | 0.040 |
Why?
| | Risk Assessment | 3 | 2016 | 2975 | 0.040 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2012 | 74 | 0.040 |
Why?
| | Cross Reactions | 1 | 1997 | 117 | 0.040 |
Why?
| | Nausea | 1 | 1998 | 104 | 0.040 |
Why?
| | Prognosis | 2 | 2016 | 3344 | 0.040 |
Why?
| | Drug Compounding | 1 | 2017 | 89 | 0.040 |
Why?
| | Stents | 1 | 2001 | 476 | 0.040 |
Why?
| | Meningitis, Bacterial | 1 | 1997 | 48 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1997 | 37 | 0.030 |
Why?
| | Public Health | 1 | 2021 | 434 | 0.030 |
Why?
| | Particle Size | 1 | 1997 | 317 | 0.030 |
Why?
| | Migraine Disorders | 1 | 1997 | 82 | 0.030 |
Why?
| | Kidney | 1 | 2003 | 1184 | 0.030 |
Why?
| | Cross-Over Studies | 2 | 2012 | 441 | 0.030 |
Why?
| | Hip Prosthesis | 1 | 1996 | 33 | 0.030 |
Why?
| | Atovaquone | 1 | 1995 | 2 | 0.030 |
Why?
| | Appendicitis | 1 | 1997 | 109 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 1997 | 524 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 144 | 0.030 |
Why?
| | Catheterization | 1 | 2016 | 160 | 0.030 |
Why?
| | Aminoglycosides | 1 | 1995 | 13 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1995 | 195 | 0.030 |
Why?
| | Liver Failure | 1 | 1995 | 75 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 171 | 0.030 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 15 | 0.030 |
Why?
| | Bradycardia | 1 | 2014 | 48 | 0.030 |
Why?
| | Seizures | 1 | 2017 | 340 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 62 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 36 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 41 | 0.030 |
Why?
| | Everolimus | 1 | 2014 | 61 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2014 | 48 | 0.030 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 7 | 0.030 |
Why?
| | Child, Preschool | 4 | 2007 | 9086 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 286 | 0.030 |
Why?
| | Haemophilus Infections | 1 | 1993 | 28 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 62 | 0.030 |
Why?
| | Esophageal and Gastric Varices | 1 | 2013 | 31 | 0.030 |
Why?
| | Safety | 1 | 1995 | 297 | 0.030 |
Why?
| | Rats | 1 | 2001 | 4963 | 0.030 |
Why?
| | Pleural Effusion | 1 | 2013 | 47 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 333 | 0.030 |
Why?
| | Demography | 1 | 2014 | 262 | 0.030 |
Why?
| | Hypotension | 1 | 2014 | 113 | 0.030 |
Why?
| | Disaster Planning | 1 | 2014 | 74 | 0.030 |
Why?
| | Torsades de Pointes | 1 | 2013 | 17 | 0.030 |
Why?
| | Salmonella Infections | 1 | 1993 | 50 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1325 | 0.030 |
Why?
| | Methylmethacrylates | 1 | 1992 | 4 | 0.030 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.030 |
Why?
| | Pneumococcal Infections | 1 | 1993 | 91 | 0.030 |
Why?
| | New York | 2 | 1993 | 106 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2014 | 539 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1844 | 0.030 |
Why?
| | 4-Quinolones | 1 | 1992 | 1 | 0.030 |
Why?
| | Societies, Medical | 1 | 2016 | 677 | 0.030 |
Why?
| | Arthroplasty | 1 | 1992 | 50 | 0.030 |
Why?
| | Survival Rate | 1 | 2016 | 1644 | 0.030 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2012 | 22 | 0.020 |
Why?
| | Infant | 3 | 2007 | 7937 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 1993 | 196 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2012 | 53 | 0.020 |
Why?
| | Barbiturates | 1 | 1991 | 4 | 0.020 |
Why?
| | Education, Nursing, Continuing | 1 | 2011 | 37 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2016 | 678 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 378 | 0.020 |
Why?
| | Hepacivirus | 1 | 2013 | 229 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1993 | 256 | 0.020 |
Why?
| | Antibodies | 1 | 1993 | 372 | 0.020 |
Why?
| | Decision Trees | 1 | 2010 | 80 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 49 | 0.020 |
Why?
| | Hospitals | 1 | 1995 | 581 | 0.020 |
Why?
| | Midwestern United States | 1 | 2010 | 38 | 0.020 |
Why?
| | Gastroesophageal Reflux | 1 | 2013 | 234 | 0.020 |
Why?
| | Professional Role | 1 | 2011 | 152 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 85 | 0.020 |
Why?
| | Canada | 1 | 1991 | 322 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 1988 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 227 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2013 | 386 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1372 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1775 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 297 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2010 | 151 | 0.020 |
Why?
| | Hepatitis C | 1 | 2011 | 219 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2010 | 244 | 0.020 |
Why?
| | Sex Factors | 2 | 2009 | 1721 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 323 | 0.020 |
Why?
| | Blood Pressure | 2 | 2004 | 1537 | 0.020 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 22 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 582 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 486 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 675 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 978 | 0.020 |
Why?
| | Anxiety | 1 | 2013 | 846 | 0.020 |
Why?
| | Patient Care Team | 1 | 2011 | 516 | 0.020 |
Why?
| | Burn Units | 1 | 2007 | 26 | 0.020 |
Why?
| | Cellulitis | 1 | 2007 | 45 | 0.020 |
Why?
| | Hospitals, University | 1 | 2007 | 171 | 0.020 |
Why?
| | Seasons | 1 | 1988 | 449 | 0.020 |
Why?
| | Colistin | 1 | 2005 | 8 | 0.020 |
Why?
| | Polymyxin B | 1 | 2005 | 21 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2006 | 89 | 0.020 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 7 | 0.020 |
Why?
| | Depression | 1 | 2013 | 1134 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2014 | 4427 | 0.020 |
Why?
| | Cell Count | 1 | 2006 | 305 | 0.020 |
Why?
| | Hypertension | 1 | 2013 | 1059 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1801 | 0.020 |
Why?
| | Methotrexate | 1 | 2006 | 228 | 0.010 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 6 | 0.010 |
Why?
| | Ceftazidime | 1 | 2004 | 5 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2006 | 387 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 63 | 0.010 |
Why?
| | Tobramycin | 1 | 2004 | 47 | 0.010 |
Why?
| | Urine | 1 | 2004 | 55 | 0.010 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 38 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1993 | 3549 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 3418 | 0.010 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 102 | 0.010 |
Why?
| | Hospitals, Urban | 1 | 2004 | 127 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 1813 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 915 | 0.010 |
Why?
| | Skin Diseases | 1 | 2004 | 122 | 0.010 |
Why?
| | Hospital Mortality | 1 | 2007 | 776 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2770 | 0.010 |
Why?
| | Tablets | 1 | 2002 | 36 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 392 | 0.010 |
Why?
| | Physicians | 1 | 2010 | 772 | 0.010 |
Why?
| | Intestinal Absorption | 1 | 2002 | 93 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2002 | 125 | 0.010 |
Why?
| | Coronary Thrombosis | 1 | 2001 | 25 | 0.010 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2001 | 128 | 0.010 |
Why?
| | Gamma Rays | 1 | 2001 | 48 | 0.010 |
Why?
| | Heart Rate | 1 | 2004 | 705 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 2001 | 245 | 0.010 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2001 | 146 | 0.010 |
Why?
| | Trigeminal Ganglion | 1 | 1999 | 21 | 0.010 |
Why?
| | Inhibitory Concentration 50 | 1 | 1999 | 75 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2003 | 604 | 0.010 |
Why?
| | Virus Shedding | 1 | 1999 | 39 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2096 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2001 | 221 | 0.010 |
Why?
| | Virus Latency | 1 | 1999 | 80 | 0.010 |
Why?
| | Rabbits | 1 | 1999 | 748 | 0.010 |
Why?
| | Homeostasis | 1 | 2002 | 576 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2001 | 1126 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2001 | 400 | 0.010 |
Why?
| | Serum Albumin | 1 | 1996 | 134 | 0.010 |
Why?
| | Elective Surgical Procedures | 1 | 1996 | 151 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2001 | 929 | 0.010 |
Why?
| | Nymph | 1 | 1993 | 4 | 0.010 |
Why?
| | Saliva | 1 | 1993 | 189 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1996 | 2133 | 0.000 |
Why?
|
|
Fish's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|